Is prochlorperazine (Stemetil) causing anxiety and what is the appropriate treatment?

Prochlorperazine (Stemetil) Can Cause Anxiety and Akathisia

Yes, prochlorperazine (Stemetil) commonly causes anxiety-like symptoms, primarily through akathisia (motor restlessness), which occurs in 14-16% of patients and can be difficult to distinguish from primary anxiety disorders. 1, 2, 3

Understanding the Problem

Prochlorperazine causes extrapyramidal side effects (EPS) that manifest as:

• Akathisia (motor restlessness with subjective anxiety) develops in 16% of patients after a single 10 mg IV dose within 1 hour, and 14% with oral dosing 2, 3, 4
• The akathisia presents as restlessness, inability to sit still, and intense subjective anxiety that can be mistaken for primary psychiatric illness 1
• Dystonia occurs in 4% of patients 3
• These symptoms typically appear within 1 week of starting treatment, with most cases occurring within the first hour after IV administration 2, 4

High-Risk Populations

Certain patients have increased susceptibility to these reactions 1:

• Patients under 30 years old
• Women (possibly)
• Patients with AIDS
• Those with renal disease
• Oncology patients

Treatment Algorithm

Immediate Management

Stop prochlorperazine immediately when akathisia or anxiety symptoms develop 1, 4

Pharmacologic Treatment Options

1. Switch to an atypical antipsychotic antiemetic:

   • Olanzapine 5-10 mg PO daily is the preferred alternative, with significantly lower EPS rates (0% akathisia in comparative studies) 5, 4
   • Perospirone 4-8 mg/day showed 0% extrapyramidal symptoms versus 14% with prochlorperazine 4

2. If continuing antiemetic therapy is needed, use alternative classes:

   • 5-HT3 antagonists (ondansetron 8 mg PO/IV, granisetron 1-2 mg PO) as first-line alternatives 6, 5
   • Metoclopramide 10-20 mg (though this also carries EPS risk, it may be lower than prochlorperazine) 6

3. For acute akathisia symptoms while transitioning:

   • Benzodiazepines: Lorazepam 0.5-2 mg PO/IV every 6 hours can manage the anxiety component 5
   • Anticholinergic agents (diphenhydramine 25-50 mg) may help with acute dystonic reactions 7

Prevention Strategy

Do not use prochlorperazine as first-line for anxiety - the FDA label explicitly states it is not the first drug for non-psychotic anxiety due to risks including irreversible tardive dyskinesia with prolonged use (>20 mg/day or >12 weeks) 8

Clinical Pitfalls

• Misdiagnosis risk: Akathisia can present identically to primary anxiety, depression, or even catatonia, leading to inappropriate escalation of psychiatric medications rather than stopping the causative agent 1
• Delayed recognition: Physicians may not connect anxiety symptoms to an antiemetic started days earlier 1
• Inadequate patient counseling: Patients should be warned about these potential side effects before starting treatment 3

Preferred Antiemetic Alternatives

For nausea/vomiting without EPS risk 6, 5:

• Ondansetron 8 mg IV/PO (minimal EPS)
• Granisetron 1 mg IV or 2 mg PO (minimal EPS)
• Olanzapine 5-10 mg PO (effective antiemetic with lower EPS than prochlorperazine)
• Dexamethasone 4-12 mg IV/PO (no EPS risk)